Screening for metabolic dysfunction-associated steatohepatitis, or MASH, often hits a wall when providers try to move beyond theory. Dr. Nadege Gunn outlined a tiered, scalable algorithm in her recent discussion that prioritizes the FIB-4 score as the first-line tool across various guidelines. It is a simple calculation using AST, ALT, platelets, and age that yields an actionable number, with a result of 1.3 or higher signaling potential at-risk fibrosis and the need for further evaluation, and that can be performed universally regardless of clinical setting or geographic location. [1]Providers move beyond theory to find scalable options.
A Two-Tiered Approach to Liver Health
The algorithm functions on a tiered structure. If the initial FIB-4 result indicates risk, clinicians should move to a second tier. Elastography is the preferred next step where available, providing quantification of both liver stiffness and fat content. The Enhanced Liver Fibrosis test offers a validated blood-based alternative for settings where elastography is not accessible. Gunn clarified that an abnormal secondary test should prompt referral to a hepatologist or gastroenterologist experienced in MASH for definitive diagnosis and care linkage.
Not every patient requires immediate specialist intervention. Gunn acknowledged that patients with early disease and no competing processes can often be managed effectively in the primary care setting. This reinforces that the FIB-4 remains the cornerstone of any population-based screening strategy precisely because of its scalability. However, the diagnostic path can become tangled for providers who lack immediate access to advanced imaging or specialized hepatology clinics.
Efficiently routing these patients through the healthcare system requires a clear chain of command. If a general practitioner detects a red flag on a standard blood panel, the pathway to a specialist must be seamless. Otherwise, the screening intent is lost in administrative red tape. The practical success of any screening program depends entirely on the ability to connect the initial risk calculation to the definitive care a patient actually receives.
Future Outlook and Patient Management
Gunn emphasized that while the FIB-4 score provides a necessary starting point, it is not a final destination. It acts as a gateway to more definitive testing rather than a diagnosis itself. The ultimate goal involves managing the underlying metabolic drivers of the disease, which includes lifestyle modifications and pharmacological interventions tailored to the individual’s specific metabolic profile. Without addressing these root causes, the progression of liver fibrosis can continue unchecked.
The implementation of such algorithms faces significant challenges regarding access and resources. Rural clinics or underserved communities often lack the infrastructure for elastography or the specialized training required for advanced interpretation. Consequently, reliance on a single calculation can leave gaps in care for those populations. This disparity highlights the urgent need for more accessible diagnostic tools that do not compromise the quality of the assessment.
